Skye Bioscience, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing G-protein-coupled receptor modulators for obesity and metabolic health. Form 8-K reports cover financial results, corporate updates, Reg FD clinical communications for nimacimab and the CBeyond program, and material events tied to executive transitions, equity compensation and Nasdaq listing-compliance matters.
The company's proxy materials address annual meeting voting, director elections, executive compensation, pay-versus-performance tables, equity awards and incentive-plan governance. Compensation-related filings also describe stock-option repricing under Skye equity incentive plans and related common-stock disclosures.
Skye Bioscience is a clinical-stage biotech focused on treating obesity, overweight and metabolic disorders by modulating G‑protein‑coupled receptors. Its lead antibody, nimacimab, is a peripherally restricted negative allosteric modulator of the CB1 receptor designed to avoid brain-related safety issues seen with earlier small-molecule CB1 drugs.
Preclinical models showed dose‑dependent weight loss with fat mass reduction and lean mass preservation, plus durable effects and synergy when combined with incretin therapies. In the CBeyond Phase 2a trial, nimacimab 200 mg weekly did not meet the primary endpoint as monotherapy but, combined with semaglutide, produced greater mean weight loss (−13.2% versus −10.25%) and improved waist circumference, body composition and reduced rebound weight gain, with a placebo‑like safety profile. Interim extension data suggest continued benefit through 52 weeks. Skye is running an IV expansion study, planning a potential Phase 2b combination trial, has a subcutaneous delivery collaboration with Halozyme’s ENHANZE technology, and reports a global IP portfolio with patents extending into the mid‑2030s and beyond.
Skye Bioscience announced that Chief Financial Officer Kaitlyn Arsenault will step down effective February 20, 2026 to pursue new professional opportunities and will continue as an advisor. Under a Separation and Release Agreement, she will receive a $450,000 cash severance, an additional $45,000 toward her 2026 annual bonus, reimbursement of up to $30,000 in legal fees, and a lump-sum payment of $41,172.48 equal to 12 months of COBRA premiums.
Certain outstanding equity awards will continue to vest during her advisory term, and unvested awards will fully vest if a Change in Control occurs within a year and before the advisory role ends. Vested stock options will remain exercisable until the later of February 20, 2027 or 90 days after the advisory term ends. The company states her departure is not due to any disagreement on financial reporting or company practices. In connection with this change, the Board appointed CEO Punit Dhillon as principal accounting officer, with his existing compensation and roles otherwise unchanged.
Skye Bioscience director receives stock option grant. Director Andrew J. Schwab was granted a stock option for 35,000 shares of Skye Bioscience, Inc. common stock on February 6, 2026. The option has an exercise price of $0.82 per share and was awarded at no cost to him.
The option vests in equal monthly installments over a one-year period beginning January 19, 2026, and is exercisable until February 6, 2036. Following this grant, Schwab holds 35,000 derivative securities directly in the form of this stock option.
Skye Bioscience director Grayson Paul A. received a grant of stock options on February 6, 2026. The award covers 35,000 stock options to buy Skye Bioscience common stock at an exercise price of $0.82 per share, held as a direct ownership position.
According to the footnote, the option vests in equal monthly installments over a one-year period beginning January 19, 2026. After this transaction, the director beneficially holds 35,000 derivative securities related to Skye Bioscience common stock.
Skye Bioscience director Karen L. Smith reported receiving a stock option award. On 02/06/2026 she was granted an option to buy 35,000 shares of common stock at an exercise price of $0.82 per share. The option vests in equal monthly installments over the one-year period beginning January 19, 2026, and all 35,000 derivative securities are held directly.
Skye Bioscience reported that its Chief Financial Officer, Kaitlyn Arsenault, received a grant of stock options on February 6, 2026. The award covers 125,000 options to buy common stock at an exercise price of $0.82 per share. The options vest in equal monthly installments over a four-year period beginning January 19, 2026, aligning her long-term compensation with the company’s share performance.
Skye Bioscience Chief Scientific Officer granted 150,000 stock options. Christopher Twitty received a stock option for 150,000 shares of common stock at an exercise price of $0.82 per share on February 6, 2026. All 150,000 options are held directly.
The option vests in equal monthly installments over a four-year period beginning January 19, 2026, meaning portions become exercisable each month over that timeframe rather than all at once.
Skye Bioscience director Deborah H. Charych received stock options for 35,000 shares of common stock. The options have an exercise price of $0.82 per share and were granted on February 6, 2026. They vest in equal monthly installments over a one-year period beginning January 19, 2026, and expire on February 6, 2036.
Skye Bioscience director Annalisa Jenkins received a grant of stock options covering 35,000 shares of common stock on February 6, 2026. The options have an exercise price of $0.82 per share and expire on February 6, 2036.
According to the filing, the option vests in equal monthly installments over a one-year period beginning January 19, 2026. After this grant, Jenkins beneficially owns 35,000 stock options, held directly.
Skye Bioscience Chief Development Officer granted 125,000 options to buy common stock at an exercise price of $0.82 per share. The award was made on February 6, 2026 and expires on February 6, 2036.
The stock option vests in equal monthly installments over four years beginning January 19, 2026, meaning the officer earns the right to exercise more of the grant every month during that period, as long as service conditions are met.